Christopher I Wright
CIK 1838503 · Chief Medical Officer · last filed 2026-06-12
Christopher I Wright is a Chief Medical Officer who has filed 15 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for ALKS, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$100.7K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALKS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 BURLINGTON ROAD
DUBLIN 4, L2 D04 C5Y6
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 25,680 | $44.44 | $1.14M | -$90.2K | 13 | 2026-06-12 |
| Cyclerion Therapeutics, Inc. (CYCN) Delisted | Chief Medical Officer | 305 | $23.52 | $7.2K | -$10.5K | 1 | 2021-03-01 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | ALKS | Notice (144) | −2,000 | -$90.2K | EDGAR |
| 2026-06-12 | ALKS | Sell (S) | −2,000 | -$90.2K | EDGAR |
| 2026-05-22 | ALKS | Mixed | +4,667 | -$54.5K | EDGAR |
| 2025-06-10 | ALKS | Mixed | +2,508 | -$25.1K | EDGAR |
| 2025-06-02 | ALKS | Mixed | +6,089 | -$58.9K | EDGAR |
| 2025-05-23 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2024-07-01 | ALKS | Mixed | +4,639 | -$35.3K | EDGAR |
| 2024-06-10 | ALKS | Mixed | +2,508 | -$19.0K | EDGAR |
| 2024-06-04 | ALKS | Mixed | — | $0 | EDGAR |
| 2023-07-10 | ALKS | Mixed | +4,527 | -$42.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.